5 research outputs found

    Distribution of the 107 peptides found associated with empagliflozin treatment in the cohort investigated.

    No full text
    <p>Each peptide is displayed based on the mass (in kDa, using a logarithmic scale) and migration time (in minutes). The average relative abundance is represented by the peak intensity. To depict also the lower abundant peptides, the same 107 peptides with abundance magnified 10-fold are shown on the right. Panel A shows the distribution of the 107 peptides before treatment, panel B depicts the distribution after treatment. To ease assessment of changes, the data from patients before and after treatment were superimposed in panel C, peaks were labeled red before EMPA treatment and green after EMPA treatment, the yellow fraction of the peak indicates the overlap in abundance between before and after treatment.</p

    Box-Whisker blots of the scoring representing the proteome changes induced as a result of empagliflozin treatment.

    No full text
    <p>The clear separation of the groups prior and after treatment is evident. However, when applying this classifier to a cohort of CKD patients and controls, the controls score slightly, yet significantly (p<0.01) higher (indicative of empagliflozin treatment) than the CKD patients.</p

    sj-docx-1-cms-10.1177_12034754241230690 – Supplemental material for Development of Vitiligo in Patients Treated With BRAF/MEK Inhibitors: A Systematic Review

    No full text
    Supplemental material, sj-docx-1-cms-10.1177_12034754241230690 for Development of Vitiligo in Patients Treated With BRAF/MEK Inhibitors: A Systematic Review by Nancy Liu, Nawar Tarafdar, Jorge R. Georgakopoulos, Khalad Maliyar, Muskaan Sachdeva, Yuliya Lytvyn, Asfandyar Mufti and Jensen Yeung in Journal of Cutaneous Medicine and Surgery</p
    corecore